Last reviewed · How we verify
STN1010904 ophthalmic suspension 0.1% BID — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
STN1010904 ophthalmic suspension 0.1% BID (STN1010904 ophthalmic suspension 0.1% BID) — Santen Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| STN1010904 ophthalmic suspension 0.1% BID TARGET | STN1010904 ophthalmic suspension 0.1% BID | Santen Inc. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- STN1010904 ophthalmic suspension 0.1% BID CI watch — RSS
- STN1010904 ophthalmic suspension 0.1% BID CI watch — Atom
- STN1010904 ophthalmic suspension 0.1% BID CI watch — JSON
- STN1010904 ophthalmic suspension 0.1% BID alone — RSS
Cite this brief
Drug Landscape (2026). STN1010904 ophthalmic suspension 0.1% BID — Competitive Intelligence Brief. https://druglandscape.com/ci/stn1010904-ophthalmic-suspension-0-1-bid. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab